Biologics/Immunotherapy News

Patients with severe eosinophilic asthma who used depemokimab administered every 6 months experienced a 54% reduction in exacerbations over 52 weeks, according to a study presented at the European Respiratory Society International Congress.

Patients with greater impairment before initiating biologic treatment for asthma had better response across all assessed outcomes, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Sublingual immunotherapy for house dust mite allergy improved allergic rhinitis symptoms among children aged 1 to 4 years over 12 months, according to a study published in Pediatric Allergy and Immunology.

The field of food allergy treatment has been evolving rapidly, with several promising developments in recent years. Typically, much of what makes headlines, though, surrounds who pays for the headlines.

The ADAPT OIT program builds peanut tolerance in babies with daily dosing of peanut powder administered by caregivers at home, according to a National Allergy Centre of Excellence and Murdoch Children’s Research Institute press release.

DBV Technologies recently provided updates on its Viaskin Peanut Program for children and toddlers, announcing recruitment for the VITESSE study and progress in the COMFORT Toddlers supplemental safety study.

SAN ANTONIO — Clinicians and researchers are beginning to explore whether asthma remission is possible, Corinne Young, FNP-C, FCCP, said during her presentation at the 16th Annual Allergy, Asthma & Immunology CME Conference.

SAN ANTONIO — Personalized treatment strategies can help providers overcome barriers to biologic care for patients with asthma, Lukena Karkhanis, MD, said at the 16th Annual Allergy, Asthma & Immunology CME Conference.

The FDA approved an expanded label for Xembify, a 20% subcutaneous immunoglobulin used to treat primary immunodeficiencies produced by Grifols, according to a company press release.